The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia
Open accessAbstract
Key Points: Daratumumab is effective against T-ALL in human xenograft models. CD38 is a novel target with broad potential in the treatment of T-ALL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596 · cited 1×
“This panel included 10 patients with early T cell precursor (ETP) ALL, a subtype characterized by a distinct immunophenotype, poor initial response to chemotherapy, and inferior outcome.(9,11-14) We observed robust CD38 expression at baseline in 21 of 21 patients tested (11 non-ETP T-ALL and 10 ETP T-ALL) (Figure 1A).”
BackgroundSelf-citationTargeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · cited 1×
“Daratumumab is an FDA-approved human IgG1κ monoclonal antibody that binds to a specific epitope of CD38 and is well tolerated and effective in relapsed multiple myeloma (MM).(3-7)”
Background
Cited by
Malard, F., & Mohty, M. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33018-1 · Cited by 773
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
van de Donk, N. W. C. J., & Usmani, S. Z. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02134 · Cited by 354
Comparative features and outcomes between paediatric T-cell and B-cell acute lymphoblastic leukaemia
Teachey, D. T., & Pui, C.-H. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30031-2 · Cited by 291
Self-citationPoly(ADP-Ribose) Polymerases in Host-Pathogen Interactions, Inflammation, and Immunity
Brady, P. N., Goel, A., & Johnson, M. A. (2019) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00038-18 · Cited by 58
Metadata
- Authors
- Bride, K. L., Vincent, T. L., Im, S.-Y., Aplenc, R., Barrett, D. M., Carroll, W. L., Carson, R., Dai, Y., Devidas, M., Dunsmore, K. P., Fuller, T., Glisovic-Aplenc, T., Horton, T. M., Hunger, S. P., Loh, M. L., Maude, S. L., Raetz, E. A., Winter, S. S., Grupp, S. A., Hermiston, M. L., Wood, B. L., & Teachey, D. T.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2018-03-01
- Volume
- 131
- Issue
- 9
- Pages
- 995-999
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2781552270
- Cited by
- 229
- References
- 2
- FWCI
- 21.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. https://app.cochat.ai/papers/10.1182/blood-2017-07-794214
- The paper
- Bride, K. L., Vincent, T. L., Im, S.-Y., Aplenc, R., Barrett, D. M., Carroll, W. L., Carson, R., Dai, Y., Devidas, M., Dunsmore, K. P., Fuller, T., Glisovic-Aplenc, T., Horton, T. M., Hunger, S. P., Loh, M. L., Maude, S. L., Raetz, E. A., Winter, S. S., Grupp, S. A., . . . Teachey, D. T. (2018). Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. https://doi.org/10.1182/blood-2017-07-794214
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.